**Supplemental Digital Content 9.** Proportion and Duration of Third-line Monotherapy by Medication

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Medication** | | **Total**  **N=796** | **Commercial n=508** | **Medicare n=288** |
| Carbamazepine, third-line monotherapy, n (%) | | 247 (31.0) | 155 (30.5) | 92 (31.9) |
| Duration (days) | Median (IQR) | 33 (30–107) | 30 (30–104) | 39 (30–124) |
| Mean (SD) | 108 (172) | 91 (134) | 135 (219) |
| Gabapentin, third-line monotherapy, n (%) | | 238 (29.9) | 143 (28.2) | 95 (33.0) |
| Duration (days) | Median (IQR) | 46 (30–109) | 45 (30–109) | 47 (30–110) |
| Mean (SD) | 96 (131) | 92 (118) | 103 (149) |
| Oxcarbazepine, third-line monotherapy, n (%) | | 98 (12.3) | 60 (11.8) | 38 (13.2) |
| Duration (days) | Median (IQR) | 36 (30–90) | 30 (23–90) | 51 (30–90) |
| Mean (SD) | 111 (204) | 107 (212) | 117 (193) |
| Pregabalin, third-line monotherapy, n (%) | | 97 (12.2) | 61 (12.0) | 36 (12.5) |
| Duration (days) | Median (IQR) | 34 (30–158) | 34 (30–140) | 37 (8–239) |
| Mean (SD) | 122 (168) | 105 (131) | 152 (216) |
| Topiramate, third-line monotherapy, n (%) | | 50 (6.3) | 44 (8.7) | 6 (2.1) |
| Duration (days) | Median (IQR) | 30 (28–75) | 30 (22–75) | 41 (30–58) |
| Mean (SD) | 68 (86) | 71 (91) | 49 (27) |
| Duloxetine, third-line monotherapy, n (%) | | 33 (4.2) | 20 (3.9) | 13 (4.5) |
| Duration (days) | Median (IQR) | 86 (30–187) | 45 (30–155) | 159 (82–337) |
| Mean (SD) | 156 (174) | 114 (134) | 222 (211) |
| Baclofen, third-line monotherapy, n (%) | | 33 (4.2) | 25 (4.9) | 8 (2.8) |
| Duration (days) | Median (IQR) | 47 (28–156) | 75 (28–156) | 39 (19–143) |
| Mean (SD) | 140 (193) | 156 (211) | 93 (116) |

IQR, interquartile range.